Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Century Health, now with $2M, taps AI to give pharma access to good patient data | TechCrunch

Mar 27, 2024 - techcrunch.com
Nvidia and Century Health are among the companies leveraging artificial intelligence (AI) to uncover hidden signals in healthcare data. Nvidia recently announced two dozen new AI-powered tools for areas such as biotechnology and drug discovery. Century Health, a startup co-founded by Vish Srivastava and Sanjay Hariharan, is using AI to analyze clinical data and discover new drug applications. The company is partnering with pharmaceutical companies and researchers at Yale and UC San Diego to identify and commercialize treatments for diseases like Alzheimer's.

Century Health has developed a platform that extracts and aggregates hidden data, which researchers and pharma companies can subscribe to for insights on approved drugs and potential new ones. The startup, which recently secured $2 million in pre-seed funding, plans to run three to five pilots in the coming months to validate its technology and assess the impact of the insights it can provide. The funding round was led by 2048 Ventures, with participation from LifeX, Everywhere, Alumni Ventures, and angel investors including Datavant founder Travis May and Evidation founder and CEO Christine Lemke.

Key takeaways:

  • Nvidia and startup Century Health are using AI to find hidden signals in healthcare data, with applications in areas like biotechnology and drug discovery.
  • Century Health, co-founded by Vish Srivastava and Sanjay Hariharan, is working with pharmaceutical companies and researchers to identify and commercialize new treatments for diseases like Alzheimer's.
  • The company has built a platform that extracts and aggregates hidden data, which researchers and pharma companies can subscribe to for insights on approved drugs and potential new drugs.
  • Century Health has secured $2 million in pre-seed funding and plans to run three to five pilots over the next several months to validate its technology and assess the impact of the insights it can provide.
View Full Article

Comments (0)

Be the first to comment!